Physician profile
Amjad Kabach
NPI 1891137758
$7,979.46
in general payments reported to CMS, 2019-2025
17 companies · $5,558 in 2025
The $5,558 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $109 · 2021: $387 · 2022: $358 · 2023: $576 · 2024: $773 · 2025: $5,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,800 · Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,800.00 |
| Food and Beverage | $2,106.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,801.62 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $445.82 | 2020-2025 | |
| Astellas Pharma US INC | $397.98 | 2021-2022 | |
| Amgen INC. | $319.87 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $240.08 | 2024 | Linq II |
| Pfizer INC. | $231.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.16 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.09 | 2019-2022 | |
| Scpharmaceuticals INC. | $91.05 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $55.76 | 2019-2021 | |
| Chiesi USA, INC. | $46.91 | 2019-2021 | |
| Esperion Therapeutics, INC. | $18.72 | 2023 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $17.69 | 2023 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $17.52 | 2025 | Wainua |
| Amarin Pharma, INC. | $15.36 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.81 | 2023 | Verquvo |
| Abbott Laboratories | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Kabach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.